Journal List > J Korean Soc Radiol > v.79(3) > 1099990

Son, Lee, Jeong, Kim, Suh, and Lee: Study of the Efficacy of PET/CT in Lung Aspiration Biopsy and Factors Associated with False-Negative Results

Abstract

Purpose

We compared the outcomes of percutaneous transthoracic needle aspiration biopsy (PCNA) of lung masses in cases with and without prior positron emission tomography/computed tomography (PET/CT) information, and investigated the factors associated with false-negative pathological results.

Materials and Methods

From a total of 291 patients, 161 underwent PCNA without prior PET/CT imaging, while 130 underwent PET/CT before PCNA. Clinical characteristics, procedural variables, pathological results, and diagnostic success rates were compared between the 2 groups. Among patients with initial negative (non-specific benign) PCNA results, the radiological findings of these groups were compared to evaluate the predictors of false-negative lesions.

Results:

No significant difference was found in the clinical characteristics, procedural characteristics, and pathological results of the 2 groups, nor was the diagnostic rate significantly different between them (p = 0.818). Among patients with initial negative PCNA results, radiological characteristics were similar in both the groups. In multivariate analysis, the presence of necrosis (p = 0.005) and ground-glass opacity (GGO) (p = 0.011) were the significant characteristics that indicated an increased probability of initial false-negative results in PCNA.

Conclusion

Routine PET/CT did not have any additional benefit in patients undergoing PCNA of lung masses. The presence of necrosis or GGO could indicate an increased probability of false-negative pathological results.

REFERENCES

1.National Lung Screening Trial Research Team. Church TR., Black WC., Aberle DR., Berg CD., Clingan KL, et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013. 368:1980–1991.
crossref
2.Hoffman JM., Gambhir SS. Molecular imaging: the vision and opportunity for radiology in the future. Radiology. 2007. 244:39–47.
crossref
3.Bomanji JB., Costa DC., Ell PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol. 2001. 2:157–164.
crossref
4.Cornelis F., Silk M., Schoder H., Takaki H., Durack JC., Erinjeri JP, et al. Performance of intra-procedural 18-fluorodeoxy-glucose PET/CT-guided biopsies for lesions suspected of malignancy but poorly visualized with other modalities. Eur J Nucl Med Mol Imaging. 2014. 41:2265–2272.
crossref
5.Klaeser B., Mueller MD., Schmid RA., Guevara C., Krause T., Wiskirchen J. PET-CT-guided interventions in the management of FDG-positive lesions in patients suffering from solid malignancies: initial experiences. Eur Radiol. 2009. 19:1780–1785.
crossref
6.Guralnik L., Rozenberg R., Frenkel A., Israel O., Keidar Z. Metabolic PET/CT-guided lung lesion biopsies: impact on diagnostic accuracy and rate of sampling error. J Nucl Med. 2015. 56:518–522.
crossref
7.Purandare NC., Kulkarni AV., Kulkarni SS., Roy D., Agrawal A., Shah S, et al. 18F-FDG PET/CT-directed biopsy: does it offer incremental benefit? Nucl Med Commun. 2013. 34:203–210.
8.Stattaus J., Kuehl H., Ladd S., Schroeder T., Antoch G., Baba HA, et al. CT-guided biopsy of small liver lesions: visibility, artifacts, and corresponding diagnostic accuracy. Cardiovasc Intervent Radiol. 2007. 30:928–935.
crossref
9.Gelbman BD., Cham MD., Kim W., Libby DM., Smith JP., Port JL, et al. Radiographic and clinical characterization of false negative results from CT-guided needle biopsies of lung nodules. J Thorac Oncol. 2012. 7:815–820.
crossref
10.Hiraki T., Mimura H., Gobara H., Iguchi T., Fujiwara H., Sakurai J, et al. CT fluoroscopy-guided biopsy of 1,000 pulmonary lesions performed with 20-gauge coaxial cutting needles: diagnostic yield and risk factors for diagnostic failure. Chest. 2009. 136:1612–1617.
11.Hansell DM., Bankier AA., MacMahon H., McLoud TC., Müller NL., Remy J. Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008. 246:697–722.
crossref
12.de Geus-Oei LF., van der Heijden HF., Visser EP., Hermsen R., van Hoorn BA., Timmer-Bonte JN, et al. Chemotherapy response evaluation with 18F-FDG PET in patients with nonsmall cell lung cancer. J Nucl Med. 2007. 48:1592–1598.
crossref
13.Hicks RJ., Kalff V., MacManus MP., Ware RE., Hogg A., McKenzie AF, et al. (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed nonsmall cell lung cancer. J Nucl Med. 2001. 42:1596–1604.
14.Takeuchi S., Khiewvan B., Fox PS., Swisher SG., Rohren EM., Bassett RL Jr, et al. Impact of initial PET/CT staging in terms of clinical stage, management plan, and prognosis in 592 patients with nonsmall-cell lung cancer. Eur J Nucl Med Mol Imaging. 2014. 41:906–914.
crossref
15.Truong MT., Viswanathan C., Erasmus JJ. Positron emission tomography/computed tomography in lung cancer staging, prognosis, and assessment of therapeutic response. J Thorac Imaging. 2011. 26:132–146.
crossref
16.Cerci JJ., Pereira Neto CC., Krauzer C., Sakamoto DG., Vitola JV. The impact of coaxial core biopsy guided by FDG PET/CT in oncological patients. Eur J Nucl Med Mol Imaging. 2013. 40:98–103.
crossref
17.Klaeser B., Wiskirchen J., Wartenberg J., Weitzel T., Schmid RA., Mueller MD, et al. PET/CT-guided biopsies of metabolically active bone lesions: applications and clinical impact. Eur J Nucl Med Mol Imaging. 2010. 37:2027–2036.
crossref
18.Kim JI., Park CM., Kim H., Lee JH., Goo JM. Non-specific benign pathological results on transthoracic core-needle biopsy: how to differentiate false-negatives? Eur Radiol. 2017. 27:3888–3895.
crossref
19.Minot DM., Gilman EA., Aubry MC., Voss JS., Van Epps SG., Tuve DJ, et al. An investigation into false-negative transthoracic fine needle aspiration and core biopsy specimens. Diagn Cy-topathol. 2014. 42:1063–1068.
crossref
20.Tsukada H., Satou T., Iwashima A., Souma T. Diagnostic accuracy of CT-guided automated needle biopsy of lung nodules. AJR Am J Roentgenol. 2000. 175:239–243.
crossref
21.Yeow KM., Tsay PK., Cheung YC., Lui KW., Pan KT., Chou AS. Factors affecting diagnostic accuracy of CT-guided coaxial cutting needle lung biopsy: retrospective analysis of 631 procedures. J Vasc Interv Radiol. 2003. 14:581–588.
crossref
22.Heppner GH. Tumor heterogeneity. Cancer Res. 1984. 44:2259–2265.
crossref
23.Miles KA., Williams RE. Warburg revisited: imaging tumour blood flow and metabolism. Cancer Imaging. 2008. 8:81–86.
crossref
24.Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res. 2012. 72:4875–4882.
crossref
25.Bar-Shalom R., Yefremov N., Guralnik L., Gaitini D., Frenkel A., Kuten A, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med. 2003. 44:1200–1209.
26.Kubota K. From tumor biology to clinical PET: a review of positron emission tomography (PET) in oncology. Ann Nucl Med. 2001. 15:471–486.
crossref
27.Hua Q., Zhu X., Zhang L., Zhao Y., Tang P., Ni J. Initial experience with real-time hybrid single-photon emission computed tomography/computed tomography-guided percutaneous transthoracic needle biopsy. Nucl Med Commun. 2017. 38:556–560.
crossref
28.Aoki T., Tomoda Y., Watanabe H., Nakata H., Kasai T., Hashimoto H, et al. Peripheral lung adenocarcinoma: correlation of thin-section CT findings with histologic prognostic factors and survival. Radiology. 2001. 220:803–809.
crossref
29.Lee HY., Lee KS. Ground-glass opacity nodules: histopathology, imaging evaluation, and clinical implications. J Thorac Imaging. 2011. 26:106–118.
30.Song YS., Park CM. Pulmonary subsolid nodules: an overview & management guidelines. J Korean Soc Radiol. 2018. 78:309–320.
31.Hur J., Lee HJ., Nam JE., Kim YJ., Kim TH., Choe KO, et al. Diagnostic accuracy of CT fluoroscopy-guided needle aspiration biopsy of ground-glass opacity pulmonary lesions. AJR Am J Roentgenol. 2009. 192:629–634.
crossref
32.Kim TJ., Lee JH., Lee CT., Jheon SH., Sung SW., Chung JH, et al. Diagnostic accuracy of CT-guided core biopsy of ground-glass opacity pulmonary lesions. AJR Am J Roentgenol. 2008. 190:234–239.
crossref
33.Lu CH., Hsiao CH., Chang YC., Lee JM., Shih JY., Wu LA, et al. Percutaneous computed tomography-guided coaxial core biopsy for small pulmonary lesions with ground-glass attenuation. J Thorac Oncol. 2012. 7:143–150.
crossref
34.Suh YJ., Lee JH., Hur J., Hong SR., Im DJ., Kim YJ, et al. Predictors of false-negative results from percutaneous transthoracic fine-needle aspiration biopsy: an observational study from a retrospective cohort. Yonsei Med J. 2016. 57:1243–1251.
crossref
35.American College of Radiology. Lung-RADSTM version 1.0 assessment categories. Available at:. https://www.acr.org/-/media/ACR/Files/RADS/Lung-RADS/LungRADS_Assess-mentCategories.pdf?la=en. Published Apr 28, 2014. Accessed Aug 25. 2017.

Fig. 1
A 62-year-old male with a mass located at the right upper lobe posterior segment. PET/CT scan shows homogeneous uptake (SUVmax of 14.3), with no definite additional benefit before percutaneous transthoracic needle aspiration biopsy. Pathologic results revealed squamous cell carcinoma.
jksr-79-129f1.tif
Fig. 2
A 61-year-old female with a heterogeneous, lobulated mass with suspicious necrosis, located at the left upper lobe. PET/CT scan demonstrates high metabolic uptake at the peripheral area of the lesion (SUVmax of 16.7). Thus, the biopsy needle tip is placed at the lesion with highest metabolic uptake. Pathologic results revealed pulmonary tuberculosis. Low-dose chest CT scan (right lower quadrant) after 6 months of anti-tuberculous treatment shows interval decrease of the lesion.
jksr-79-129f2.tif
Table 1.
Clinical Characteristics, Procedure Characteristics, and Pathologic Results of Patients who Underwent Percutaneous Transthoracic Needle Aspiration Biopsy between Those with and without PET Scans
  No PET (n = 161) PET (n = 130) p-Value
Clinical characteristics
  Age (years) ± SD 64.9 ± 11.5 65.7 ± 9.1 0.506
  Sex     0.639
    Male 108 87  
    Female 53 43  
Procedure characteristics .
  Lesion size (cm) ± SD 4.7 ± 2.6 4.7 ± 2.5 0.973
  Lesion location     0.084
    Upper 104 71  
    Lower 57 59  
  Types of imaging guidance     0.498
    CT 89 77  
    Fluoroscopy 72 53  
  Position     0.400
    Supine 66 47  
    Prone 95 83  
Pathologic results
  Adequate diagnosis 141 115 0.818
    Benign 18 15  
    Malignant 123 100  
  Negative 20 15  

CT = computed tomography, PET = positron emission tomography, SD = standard deviation

Table 2.
Comparison of Radiological Characteristics among Patients with Initial Negative Percutaneous Transthoracic Needle Aspiration Biopsy Results
Radiological Characteristics No PET (n = 20) PET (n = 15) p-Value
Presence of atelectasis 2 2 0.999
Presence of necrosis 11 7 0.625
Presence of consolidation adjacent to lesion 6 4 0.999
Presence of pleural effusion 4 3 0.999
Presence of GGO 6 2 0.419

GGO = ground-glass opacity, PET = positron emission tomography

Table 3.
Comparison of Characteristics between False-Negative and True-Negative Lesions
  True Negative (n = 15) False Negative (n = 20) p-Value
Clinical characteristics
  Age (years) ± SD 62.9 ± 13.0 63.0 ± 10.6 0.973
  Sex     0.680
    Male 13 16  
    Female 2 4  
Presence of PET     0.076
  PET 9 6  
  No PET 6 14  
Radiological characteristics
  Presence of atelectasis 1 3 0.443
  Presence of necrosis 4 14 0.011∗
  Presence of consolidation adjacent to lesion 3 7 0.331
  Presence of pleural effusion 2 5 0.393
  Presence of GGO 1 7 0.101
Procedure characteristics
  Lesion size (cm) ± SD 3.0 ± 1.6 3.9 ± 2.8 0.262
  Lesion location     0.324
    Upper 10 10  
    Lower 5 10  
  Types of imaging guidance     0.163
    CT 11 10  
    Fluoroscopy 4 10  
  Position     0.693
    Supine 7 8  
    Prone 8 12  

∗Significant p-value.

CT = computed tomography, GGO = ground-glass opacity, PET = positron emission tomography, SD = standard deviation

Table 4.
Results of Univariate and Multivariate Logistic Regression Analysis for Predictors of False-Negative Lesions at Percutaneous Transthoracic Needle Aspiration Biopsy
  Univariate Multivariate
OR 95% CI p-Value OR 95% CI p-Value
Age (year) 1.001 0.944–1.062 0.972      
Sex (male) 0.615 0.097–3.908 0.607      
Presence of PET (+) 0.286 0.070–1.168 0.081 0.275 0.040–1.863 0.186
Lesion size (cm) 1.238 0.841–1.821 0.279      
Lesion location (lower) 2.000 0.500–7.997 0.327      
Types of imaging guidance (CT) 0.364 0.086–1.537 0.169      
Position (prone) 1.312 0.339–5.076 0.694      
Presence of atelectasis (+) 2.471 0.231–26.459 0.455      
Presence of necrosis (+) 6.417 1.444–28.511 0.015 34.514 2.958–402.699 0.005∗
Presence of consolidation (+) 2.154 0.451–10.287 0.336      
Presence of pleural effusion (+) 2.167 0.358–13.110 0.400      
Presence of GGO (+) 7.538 0.813–69.906 0.075 51.812 2.435–1102.354 0.011∗
OR associated with age and lesion size is that the increase in hazard is associated with a 1-year increase in age and 1-cm increase in size, respectively.
∗Significant p-value.

CI = confidence interval, CT = computed tomography, GGO = ground-glass opacity, OR = odds ratio, PET = positron emission tomography

TOOLS
Similar articles